Zoetis fundamentals remains sound, says Argus

Argus analyst Jasper Hellweg keeps a Buy rating and $190 price target on Zoetis. The animal health and vaccine industry has solid long-term growth potential, and Zoetis should be able to optimize its leadership position in the space, the analyst tells investors in a research note. The firm adds that Zoetis has been hurt by unfavorable exchange rates and supply constraints, but its overall fundamentals remain sound and shares merit a higher valuation.